Evrópusambandið - íslenska - EMA (European Medicines Agency)

recordati ireland ltd - silódósín - blóðflagnafæð - urologicals, alfa-adrenoreceptor hemla - meðferð einkenni á góðkynja stækkunar (gÓÐkynja) í fullorðnum körlum.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

recordati ireland ltd - silódósín - blóðflagnafæð - Þvaglát - meðferð á einkennum góðkynja blöðruhálskirtils (bph).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

recordati ireland ltd - silódósín - blóðflagnafæð - Þvaglát - meðferð á einkennum góðkynja blöðruhálskirtils (bph).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

sanofi belgium - alemtuzumab - margvísleg sclerosis - valdar ónæmisbælandi lyf - lemtrada er ætlað fullorðnum sjúklingum með endurtekna endurtekna mænusigg (rrms) með virkum sjúkdómum sem eru skilgreindar með klínískum eða hugsanlegum eiginleikum.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

biocryst ireland limited - berotralstat dihydrochloride - ofsabjúgur, arfgengur - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

merck sharp dohme ltd - boceprevir - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - victrelis er ætlað fyrir meðferð langvarandi lifrarbólgu-c (chc) arfgerð-1 sýkingu, ásamt sýnt alfa og sögu, í fullorðinn sjúklinga með bætt lifrarsjúkdóm sem eru áður ómeðhöndlað eða sem hafa mistekist fyrri meðferð.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - bóluefni - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - ziprasidonum hýdróklóríð - hart hylki - 20 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - ziprasidonum hýdróklóríð - hart hylki - 40 mg